ATCell

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameATCell
Drug Alias Nameexpanded autologous adipose tissue-derived stem cell therapy (American CryoStem/BioTherapeutic Labs)expanded autologous adipose tissue-derived stem cell therapy (American CryoStem/BioTherapeutic Labs)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Stem cell therapy > Adipose stem cell therapy
Mechanisms of ActionNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Wounds and InjuriesBrain Injuries, Traumatic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmerican Cryostem Corp
China Registration ClassN/A

Develop Information

Active CompaniesBioTherapeutics IncAmerican Cryostem Corp
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Brain Injuries, Traumatic
Inactive IndicationsWounds and Injuries

Other Information

ATC CodeN/A
Related LinksN/A